The pharma giant Cipla (NSE: CIPL) reported its second-quarter 20223 earnings results on Tuesday after market hours.
The total revenue increased by 10.3% to ₹5,486 crores compared to ₹4,972 crores in the previous year of the same quarter.
The company had a total net profit of ₹711 crores or ₹8.80 per share compared to ₹665 crores or ₹8.24 per share in the previous year.
Cipla’s Ebitda rose 4% YoY to ₹1,226 crores while Ebitda margin came in at 22.2%,
“In India, we continue to drive strong performance led by sustained volume traction despite a high FY21 base. Our collaboration with Eli Lily for their diabetes products helps us further strengthen our endeavour of creating access to innovative medicines in line with the One-India strategy,” said Umang Vohra, MD and Global CEO, Cipla.